LA JOLLA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) has announced the appointment of G. David Criner as the company's Chief Financial and Accounting Officer. Immunosyn's former Chief Financial and Accounting Officer, Douglas A. McCain, Jr., has been appointed as the company's Chairman of the Board and further retains his position as Corporate Secretary.
"I believe that the platform technology and its resulting biopharmaceutical product currently called SF-1019, which we have the worldwide rights to market and distribute, has the potential to positively impact the quality of life of millions of people. I am honored to be a part of its growth as the CFO of Immunosyn," says Criner.
Criner has nearly 20 years of finance and accounting experience, including extensive operational experience in senior level finance positions with multiple public and privately held marketing and high tech companies. He has held senior level finance positions at 3Com, where he was responsible for strategic planning and mergers and acquisitions, and also held leadership positions at Chartered Marketing, Iomega, Inc and Borden, Inc. Criner received his bachelor's degree in finance from Bradley University and holds a master's degree in accountancy from Weber State University.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to
market and distribute life enhancing therapeutics. Currently, the company
has exclusive worldwide rights from its largest shareholder, Argyll
Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound
that was developed from extensive research into Biological Response
Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for
regulatory approval of SF-1019 in several countries and preparations for
clinical trials are underway in both the US and Europe. Research suggests
that SF-1019 has the potential to affect a num
|SOURCE Immunosyn Corporation|
Copyright©2007 PR Newswire.
All rights reserved